Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Trial of Belinostat in Combination With Erlotinib in Patients With Non-small Cell Lung Cancer

This study has been terminated.
(Dose over MTD reached)
Sponsor:
Collaborators:
Copenhagen University Hospital at Herlev
Bispebjerg Hospital
TopoTarget A/S
Roche Pharma AG
Information provided by:
Herlev Hospital
ClinicalTrials.gov Identifier:
NCT01188707
First received: August 24, 2010
Last updated: August 3, 2011
Last verified: August 2011

August 24, 2010
August 3, 2011
December 2010
March 2012   (final data collection date for primary outcome measure)
Safety [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]
The primary purpose of the phase I part of the trial is to establish the tolerance dose (maximum tolerated dose (MTD) and dose limiting toxicity (DLT).
Same as current
Complete list of historical versions of study NCT01188707 on ClinicalTrials.gov Archive Site
Efficacy [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]
The phase II part of the study is to assess the efficacy of Belinostat and Erlotinib in combination assessed by disease control rate, defined as non - progression at 3 months / Stable disease or better) using RECIST response criteria version 1.1
Same as current
Not Provided
Not Provided
 
A Trial of Belinostat in Combination With Erlotinib in Patients With Non-small Cell Lung Cancer
A Clinical Phase I / II Trial of Belinostat in Combination With Erlotinib in Patients With Non-small Cell Lung Cancer

The Belinostat-Erlotinib trial is designed as an open, non randomized phase I / II trial to assess the efficacy and safety of Belinostat in combination with Erlotinib in patients with non-small cell lung cancer who are eligible for treatment with erlotinib.

Belinostat, developed by CuraGen, belongs to a new class of hydroxymat-type histone deacetylase (HDAC) inhibitors. HDAC inhibitors, including Belinostat, has shown marked in vitro and in vivo activity against a number of solid tumors and hematological cancers. Belinostat has proven to be effective as a single agent or in combination with other anticancer agents such as doxorubcin, paclitaxel, carboplatin, fluorouracil, bortezumib, and there has been observed synergy between Belinostat or other HDAC inhibitors and EGFR inhibitors gefinitinib and erlonitib.

Furthermore, the antineoplastic activity of Belinostat seen in preclinical experiments have resulted in only moderate toxicity.

In the two Phase I trials of Belinostat for solid tumors and hematological malignancies Belinostat have been well tolerated at doses up to 2000 mg daily in more than 100 patients.

Fatigue, nausea and vomiting has been the main side effects and with none or very mild hematologic toxicity. Approximately 25% of patients in the study of solid tumors achieved stable disease.

Interventional
Phase 1
Phase 2
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Non Small Cell Lung Cancer
Drug: Belinostat and Erlotinib

The design of the first phase is a 3 +3 phase I trial. The Belinostat dose will start at 500 mg and will be increased with 250 mg until a maximum dose of 1500 mg, administered daily in 2/3 weeks. Each patient will at the same time receive 150 mg of Erlotinib daily continously.

When the patient is enrolled at one dose level, there will be no further dose escalation for that individual patient.

3 patients will be treated at each dose level.

Other Name: Tarceva
Experimental: Belinostat, Erlotinib, NSCLC
Intervention: Drug: Belinostat and Erlotinib
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
5
August 2012
March 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Signed consent of an approved informed consent form
  2. A. For the dose escalation phase: Patients with histological or cytological confirmed non-small cell lung cancer who are rated suitable for treatment with Erlotinib B. For MTD expansion phase: Patients diagnosed with non- small cell lung cancer rated suitable for treatment with Erlotinib and with measurable disease according to RECIST version 1.1
  3. Performance status (ECOG) ≤ 2
  4. Life expectancy at least 3 months
  5. Age ≥ 18 years
  6. Acceptable liver, kidney and bone marrow function, defined as:

    • Bilirubin ≤ 1.5 x upper limit of normal (ULN)
    • ASAT, ALAT and alkaline phosphatase ≤ 3 x ULN (if liver metastases is ≤ 5 x ULN allowed)
    • Serum creatinine ≤ 1.5 x upper limit of normal (ULN)
    • WBC> 2.5 x 109 / l, neutrophils> 1.0 x 109 / l, platelets> 100 x 109 / l
    • Hemoglobin> 9.0 g / dl or> 5.6 mmol / l
  7. Acceptable coagulation: PT and APTT within ≤ 1.5 x ULN or in the therapeutic range if given anticoagulant
  8. A negative pregnancy test for women of childbearing age. In fertile men and women the use of effective contraception methods are required during the trial
  9. Serum potassium within normal range

Exclusion Criteria:

  1. Treatment with experimental drugs within the last 4 weeks
  2. Former anti-cancer therapy within the last 3 weeks before the start of experimental treatment, including chemotherapy, radiotherapy, endocrine therapy or immunotherapy
  3. Simultaneous presence of active infection or other concomitant present medical condition likely to affect the experimental procedures, including significant cardiovascular disease (New York Heart Association Class III or IV heart disease, myocardial infarction within the past 6 months, unstable angina, congestive heart failure requiring treatment, unstable arrhythmia or the need for antiarrhythmic drugs or signs of ischemia on ECG, marked baseline prolongation of QT / QTc interval, for example repeated demonstration of a QTc interval> 500 msec; long QT syndrome; required the use of concurrent medication on dosage belinostat days, which may cause torsades de pointes (see Appendix 1).
  4. Altered mental status that prevents understanding of the informed consent process and / or execution of the necessary experiments
  5. Secondary malignancy present (previous malignancy accepted if cured by treatment for > 3 years ago)
  6. Intestinal obstruction or threatening bowel obstruction
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Denmark
 
NCT01188707
LU0928
Yes
MD Jon Lykkegaard Andersen, Dept. of Oncology Copenhagen University Hospital Herlev
Herlev Hospital
  • Copenhagen University Hospital at Herlev
  • Bispebjerg Hospital
  • TopoTarget A/S
  • Roche Pharma AG
Principal Investigator: Jon L Andersen, MD Dept of Oncology Copenhagen University Hospital Herlev
Herlev Hospital
August 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP